2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Hormone Refractory Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
1033
Carboplatin
971
Paclitaxel
942
Gemcitabine
799
Cisplatin
757
Docetaxel
698
Bevacizumab
637
Nivolumab
520
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
473
Fluorouracil
425
Dexamethasone
410
Rituximab
391
Oxaliplatin
352
Injections
347
Trastuzumab
314
atezolizumab
312
Cetuximab
291
Leucovorin
290
Irinotecan
271
130-nm albumin-bound paclitaxel
257
Prednisone
251
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
219
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mycobacterium w vaccine
×
Clear all
NCT00694915
2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2
Completed
122 enrolled
NCT00680940
2012-08-07
NSCLC
Cadila Pharnmaceuticals
Phase 2
Completed
221 enrolled
NCT00694798
2012-05-03
STCC
Cadila Pharnmaceuticals
Phase 1
Completed
22 enrolled
NCT00525408
2012-03-12
HRPC
Cadila Pharnmaceuticals
Phase 2
Terminated
134 enrolled